Levi & Korsinsky notifies investors that it has commenced an investigation into Lifecore Biomedical, Inc. (NASDAQ: LFCR) concerning potential violations of the federal securities laws.
Lifecore announced on March 20, 2024, that its Board of Directors had concluded its review of strategic alternatives, in which it "unanimously concluded that the best way to maximize value for stockholders at this time is to continue executing on the Company's standalone strategic plan." The Company also announced a leadership transition by naming a new CEO. Following this news, shares of Lifecore dropped over 35% in morning trading on the same day.
If you suffered a loss on your Lifecore securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure





